PC
PCRX icon

PointState Capital’s Pacira BioSciences PCRX Stock Holding History

PointState Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-255,700
Closed -$12.6M – 124
2018
Q3 		$12.6M Sell
255,700
-1,366,984
-84% -$59.1M 0.17% 70
2018
Q2 		$52M Sell
1,622,684
-415,469
-20% -$14.3M 0.59% 43
2018
Q1 		$63.5M Buy
2,038,153
+847,146
+71% +$30.2M 0.69% 44
2017
Q4 		$54.4M Buy
1,191,007
+53,107
+5% +$2.1M 0.53% 51
2017
Q3 		$42.7M Buy
1,137,900
+566,400
+99% +$22.8M 0.36% 61
2017
Q2 		$27.3M Sell
571,500
-634,400
-53% -$29.4M 0.3% 62
2017
Q1 		$55M Buy
1,205,900
+361,900
+43% +$15.6M 0.57% 44
2016
Q4 		$27.3M Buy
844,000
+435,500
+107% +$14.5M 0.39% 63
2016
Q3 		$14M Sell
408,500
-191,500
-32% -$7.5M 0.14% 82
2016
Q2 		$20.2M Buy
600,000
+325,000
+118% +$16M 0.42% 39
2016
Q1 		$14.6M Hold
275,000
– – 0.39% 36
2015
Q4 		$21.1M Sell
275,000
-75,000
-21% -$4.25M 0.54% 33
2015
Q3 		$14.4M Buy
350,000
+25,000
+8% +$1.53M 0.4% 42
2015
Q2 		$23M Buy
325,000
+95,000
+41% +$7.48M 0.27% 63
2015
Q1 		$20.4M Buy
+230,000
New +$23.3M 0.28% 65

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PointState Capital's PCRX Position: Q4 2018 in Review

PointState Capital sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 255,700 shares — an estimated $12.6M sold.

PointState Capital first reported a position in PCRX in Q1 2015 and held it in 15 quarters. The position peaked at $63.5M in Q1 2018. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

  • PointState Capital reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
  • PointState Capital sold 255,700 Pacira BioSciences shares in Q4 2018, an estimated $12.6M.
  • PointState Capital first reported a position in Pacira BioSciences in Q1 2015 and held it in 15 quarters.
  • PointState Capital's Pacira BioSciences position peaked at $63.5M in Q1 2018.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on PointState Capital's 13F filing for Q4 2018, filed 14 Feb 2019.